Martin Shkreli

Martin Shkreli (; born March 17, 1983) is an American businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

In September 2015, Shkreli was widely criticized when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by 5,455% (from US$13.50 to $750 per pill).

In 2017, Shkreli was charged and convicted in federal court on two counts of securities fraud and one count of conspiracy for activity unrelated to the Daraprim controversy. He was sentenced to seven years in prison and up to $7.4 million in fines. In the civil antitrust (monopoly abuse) case Shkreli was fined a further $64.6 million to be repaid to victims. On May 18, 2022, he was released early from the low-security federal prison in Allenwood, Pennsylvania.